External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>Positive results from a Phase 3 clinical trial show that avasopasem reduces the severity of symptomatic oral mucositis (SOM) and decreases the need for opioid analgesics.</li><li>Galera Therapeutics plans to submit a New Drug Application (NDA) to the FDA based on these promising results.</li><li>There is potential for avasopasem to become a new standard of care for patients receiving radiation therapy for head and neck cancer.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Positive results from a Phase 3 clinical trial show that avasopasem reduces the severity of symptomatic oral mucositis (SOM) and decreases the need for opioid analgesics.Galera Therapeutics plans to submit a New Drug Application (NDA) to the FDA based on these promising results.There is potential for avasopasem to become a new standard of care for patients receiving radiation therapy for head and neck cancer.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Galera Therapeutics Inc (GRTX) - Saturday, Jul 13, 2024

United States

Galera Therapeutics, Inc. operates as a biotechnology company. The Company focuses on discovering and developing novel therapeutics to improve both the tolerability of current anti-cancer treatments and directly treat cancer. Galera Therapeutics serves healthcare sector in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Galera Therapeutics (GRTX US)

Galera Therapeutics Inc (GRTX) - Saturday, Jul 13, 2024

Positive results from a Phase 3 clinical trial show that avasopasem reduces the severity of symptomatic oral mucositis (SOM) and decreases the need...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)